Erschienen in:
01.07.2012 | Pancreatic Tumors
Clinical Significance of Folate Receptor β–expressing Tumor-associated Macrophages in Pancreatic Cancer
verfasst von:
Hiroshi Kurahara, MD, PhD, Sonshin Takao, MD, PhD, Taisaku Kuwahata, MD, Taku Nagai, PhD, Qiang Ding, MD, PhD, Koki Maeda, MD, Hiroyuki Shinchi, MD, PhD, Yuko Mataki, MD, PhD, Kosei Maemura, MD, PhD, Takami Matsuyama, MD, PhD, Shoji Natsugoe, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 7/2012
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To examine the appearance and distribution of folate receptor β-expressing (FRβ+) macrophages in the pancreatic tumor microenvironment and their relationship to metastasis and prognosis in pancreatic cancer patients.
Methods
Tumor samples were obtained from 76 patients with pancreatic cancer who underwent curative resection. None of these patients had received any preoperative chemotherapy or radiotherapy. Both FRβ+ and tumor-infiltrating (CD68+) macrophages were examined in each tumor specimen by immunohistochemical and immunofluorescence staining using a newly developed anti-human FRβ monoclonal antibody and CD68 antibody. The appearance, distribution, expression of vascular endothelial growth factor (VEGF) on FRβ-expressing or CD68+ macrophages, and tumor microvessel density (MVD) were assessed. Log rank test and Cox proportional hazard regression were used to investigate the associations among CD68+ or FRβ+ macrophages, clinicopathologic factors, and overall survival.
Results
FRβ+ macrophages were prominent in the perivascular regions of the tumor-invasive front and a specific subset with VEGF expression in the CD68+ macrophages. A high number of FRβ+ macrophages showed a positive association with high MVD, a high incidence of hematogenous metastasis, and a poor prognosis in pancreatic cancer patients.
Conclusions
FRβ+ macrophages are a novel subset of tumor-associated macrophages in pancreatic cancer and may play an important role in the tumor microenvironment in association with systemic metastasis through the interaction with tumor cells and vessels. FRβ+ macrophages may be promising a targeting therapy for pancreatic cancer.